B CELL ACTIVATION IN AUTOIMMUNITY & LYMPHOPROLIFERATION

自身免疫中的 B 细胞激活

基本信息

项目摘要

A variety of immunologic, virologic, hormonal, and genetic abnormalities have been catalogued in murine strains with with systemic lupus erythematosus (SLE)-like syndromes. However, no common link or molecular basis for such abnormalities has yet been identified. Among the various abnormalities, B cell hyperactivity leading to autoantibody production is the common and cardinal feature of all SLE murine strains, as well as of humans with SLE. Whether this B cell abnormality is primary or secondary to helper or suppresor T cell defects remains controversial and and unclear at the present. A large body of recent work indicates that proliferative and differentiative events in B and T cell development are induced by a cascade of antigen-specific and nonspecific soluble mediators elaborated by activated T cells, macrophages, and perhaps other elements of the immune systems. In order to clarify further the essential immunologic abnormalities that lead to autoimmune disorders and perhaps devise means for their molecular analysis, we propose to: (a) measure the effects of soluble T cell-derived factors with known activities on B cells of SLE and normal control murine strains; (b) assess the in vitro elaboration of soluble mediators by limphoid cells of SLE and control strains that might influence B cell differentiative and muturational processes and, if identified, determine their levels, cellular origin, mode of action, and relationship to the disease state: (c) isolate and biochemically characterize the factos, attempt to produce antibodies against them and subsequently assess the in vitro and in vivo effects of the factors and of respective antibodies; and (d) develop new lines of SLE mice defective in expression of acceptor sites for T cell-derived signals so as to ascertain the in vivo importance of the factors and of the target cell component in disease expression. These studies will clarify the means of B cell activation in systemic autoimmune diseases, provide further understanding of the interplay among lymphokines that participate in cellular and humoral immune responses, and may allow, in the future, molecular analysis and modification of this and related disorders.
各种免疫学、病毒学、激素和遗传异常 已经在系统性红斑狼疮的小鼠品系中被分类 红斑狼疮样综合征。 然而,没有共同的链接或分子 这种不正常现象的依据尚未查明。 的各种 异常,B细胞过度活跃导致自身抗体产生, 所有SLE鼠株的共同和主要特征,以及 SLE患者。 这种B细胞异常是原发性还是继发性的 辅助或抑制T细胞缺陷仍然存在争议, 在目前。 大量的近期研究表明, B和T细胞发育中的分化事件由级联反应诱导 抗原特异性和非特异性可溶性介质, 活化的T细胞,巨噬细胞,也许还有免疫系统的其他成分, 系统. 为了进一步阐明免疫学的基本原理, 导致自身免疫性疾病的异常, 对于它们的分子分析,我们建议:(a)测量 对SLE的B细胞具有已知活性的可溶性T细胞衍生因子, 正常对照鼠品系;(B)评估体外加工 可溶性介质的系统性红斑狼疮和对照菌株, 影响B细胞分化和突变过程, 确定其水平、细胞来源、作用方式,以及 与疾病状态的关系:(c)分离和生物化学 描述这些事实,试图产生抗体, 随后评估这些因子的体外和体内效应, 各自的抗体;和(d)开发新的SLE小鼠品系,其在以下方面有缺陷: T细胞来源的信号的受体位点的表达,以便确定 这些因子和靶细胞成分在体内的重要性, 疾病表达。 这些研究将阐明B细胞的意义 激活系统性自身免疫性疾病,提供进一步的了解 参与细胞和体液免疫的淋巴因子之间的相互作用 免疫反应,并可能允许,在未来,分子分析和 改变这种疾病和相关疾病。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Argyrios N Theofilopoulos其他文献

TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity
系统性自身免疫中 I 型干扰素诱导的 TLR 依赖性和 TLR 非依赖性途径
  • DOI:
    10.1038/nm1590
  • 发表时间:
    2007-05-03
  • 期刊:
  • 影响因子:
    50.000
  • 作者:
    Roberto Baccala;Kasper Hoebe;Dwight H Kono;Bruce Beutler;Argyrios N Theofilopoulos
  • 通讯作者:
    Argyrios N Theofilopoulos

Argyrios N Theofilopoulos的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Argyrios N Theofilopoulos', 18)}}的其他基金

Endolysosomal transporters and systemic autoimmunity
内溶酶体转运蛋白和系统性自身免疫
  • 批准号:
    9233919
  • 财政年份:
    2016
  • 资助金额:
    $ 13.72万
  • 项目类别:
IL-7 Biology and Role in Systemic Autoimmunity
IL-7 生物学及其在系统性自身免疫中的作用
  • 批准号:
    8719533
  • 财政年份:
    2014
  • 资助金额:
    $ 13.72万
  • 项目类别:
IL-7 Biology and Role in Systemic Autoimmunity
IL-7 生物学及其在系统性自身免疫中的作用
  • 批准号:
    9303189
  • 财政年份:
    2014
  • 资助金额:
    $ 13.72万
  • 项目类别:
The endosomal SLC15A4 proton-coupled histidine transporter in lupus
狼疮中的内体 SLC15A4 质子偶联组氨酸转运蛋白
  • 批准号:
    8598770
  • 财政年份:
    2013
  • 资助金额:
    $ 13.72万
  • 项目类别:
The endosomal SLC15A4 proton-coupled histidine transporter in lupus
狼疮中的内体 SLC15A4 质子偶联组氨酸转运蛋白
  • 批准号:
    8691735
  • 财政年份:
    2013
  • 资助金额:
    $ 13.72万
  • 项目类别:
TYPE I INTERFERONS IN LUPUS
狼疮中的 I 型干扰素
  • 批准号:
    7141837
  • 财政年份:
    2006
  • 资助金额:
    $ 13.72万
  • 项目类别:
TYPE I INTERFERONS IN LUPUS
狼疮中的 I 型干扰素
  • 批准号:
    7263842
  • 财政年份:
    2006
  • 资助金额:
    $ 13.72万
  • 项目类别:
TYPE I INTERFERONS IN LUPUS
狼疮中的 I 型干扰素
  • 批准号:
    7876912
  • 财政年份:
    2006
  • 资助金额:
    $ 13.72万
  • 项目类别:
TYPE I INTERFERONS IN LUPUS
狼疮中的 I 型干扰素
  • 批准号:
    7456427
  • 财政年份:
    2006
  • 资助金额:
    $ 13.72万
  • 项目类别:
TYPE I INTERFERONS IN LUPUS
狼疮中的 I 型干扰素
  • 批准号:
    7647051
  • 财政年份:
    2006
  • 资助金额:
    $ 13.72万
  • 项目类别:

相似海外基金

Modulation of T lymphocyte Activation by ß2-Adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
  • 批准号:
    RGPIN-2019-06980
  • 财政年份:
    2022
  • 资助金额:
    $ 13.72万
  • 项目类别:
    Discovery Grants Program - Individual
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
用于基于细胞毒性 T 淋巴细胞的癌症免疫疗法的精准肿瘤新抗原识别流程
  • 批准号:
    10581488
  • 财政年份:
    2022
  • 资助金额:
    $ 13.72万
  • 项目类别:
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
  • 批准号:
    574979-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 13.72万
  • 项目类别:
    University Undergraduate Student Research Awards
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
用于基于细胞毒性 T 淋巴细胞的癌症免疫疗法的精准肿瘤新抗原识别流程
  • 批准号:
    10332251
  • 财政年份:
    2022
  • 资助金额:
    $ 13.72万
  • 项目类别:
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
  • 批准号:
    574984-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 13.72万
  • 项目类别:
    University Undergraduate Student Research Awards
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
  • 批准号:
    574985-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 13.72万
  • 项目类别:
    University Undergraduate Student Research Awards
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
  • 批准号:
    574978-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 13.72万
  • 项目类别:
    University Undergraduate Student Research Awards
Investigating the cell-based activity of a new class of cytotoxic T-lymphocyte antigen-4 (CTLA-4) small molecule inhibitors
研究一类新型细胞毒性 T 淋巴细胞抗原 4 (CTLA-4) 小分子抑制剂的细胞活性
  • 批准号:
    444149
  • 财政年份:
    2021
  • 资助金额:
    $ 13.72万
  • 项目类别:
    Operating Grants
Novel pathways in T lymphocyte differentiation and function
T 淋巴细胞分化和功能的新途径
  • 批准号:
    RGPIN-2015-05491
  • 财政年份:
    2021
  • 资助金额:
    $ 13.72万
  • 项目类别:
    Discovery Grants Program - Individual
Modulation of T lymphocyte Activation by ß2-Adrenergic Receptor Signalling Pathways
通过 α2-肾上腺素能受体信号通路调节 T 淋巴细胞激活
  • 批准号:
    RGPIN-2019-06980
  • 财政年份:
    2021
  • 资助金额:
    $ 13.72万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了